公司股票将于2025年12月15日停牌1天，2025年12月16日起实施其他风险警示，实施其他风险警示后公 司股票将在风险警示板交易，股票价格的日涨跌幅限制为5%。 人福医药（600079）(600079.SH)发布公告，公司于2025年12月12日收到中国证券监督管理委员会湖北 监管局下发的《行政处罚事先告知书》(鄂处罚字〔2025〕8号)，依据《行政处罚事先告知书》载明的 内容，根据《上海证券交易所股票上市规则(2025年4月修订)》相关规定，公司股票将被实施其他风险 警示。实施后A股简称为ST人福。 ...

Group 1 - Moer Thread plans to use up to 7.5 billion yuan of idle raised funds for cash management, with a usage period of 12 months [1] - O-film plans to purchase 8.46% equity of its subsidiary Anhui Che Lian for a total of 3.64 billion yuan, increasing its ownership from 78.54% to 87% [2] - ST Lian Shi applies to revoke the delisting risk warning as its restructuring plan has been completed [3] Group 2 - Weirli signs a strategic cooperation framework agreement with Primech Holdings to build an industrial robot cooperation platform [4] - Race Intelligent plans to raise no more than 1.144 billion yuan through a private placement for core components of intelligent equipment [5] - Renfu Pharmaceutical's stock will be subject to other risk warnings and will be suspended for one day starting December 15 [6] Group 3 - Yongding Co. clarifies that its subsidiary Dongbu Superconductor does not directly manufacture controllable nuclear fusion devices [7] - Rongbai Technology plans to acquire part of Guizhou Xinren's equity and increase its capital to achieve control [9] - ST Hu Ke is under investigation by the Securities Regulatory Commission for suspected information disclosure violations [10] Group 4 - Yunnan Ge Industry plans to establish a subsidiary focused on organic germanium-related products [11] - Greenme intends to acquire 16.38% equity of Henan Recycling Group for 400 million yuan [12] - Jiangzhong Pharmaceutical plans to change its name to China Resources Jiangzhong Pharmaceutical [13] Group 5 - Jiangsu Guoxin's subsidiary Ma Zhou Power has completed the trial operation of a 1,000 MW coal-fired power generation unit [16] - Longsheng Technology plans to invest in a center for embodied intelligent robots [18] - Guangzhou Development has received approval for the registration of 8 billion yuan medium-term notes and 6 billion yuan short-term financing notes [19] Group 6 - China Merchants Port reported a container throughput of 17.248 million TEUs in November, a year-on-year increase of 6.4% [20] - Tianma Technology reported a total eel output of approximately 11,415.87 tons from January to November [21] Group 7 - Xilong Science plans to reduce its stake by up to 1% [22] - Xicet Testing's actual controller plans to transfer 5% of the company's shares [23] - Oppein Home's actual controller plans to increase its stake by 50 million to 100 million yuan [24] Group 8 - Maide Medical plans to repurchase shares worth 20 million to 40 million yuan [25] - Baicheng Pharmaceutical's major shareholder increased its stake by 0.85% [26] - Mengbaihe's major shareholder plans to reduce its stake by up to 1% [27] Group 9 - Xian Dao Ji Dian's shareholder has reduced its stake by 1.70% [28] - Yaxiang Integration's shareholder reduced its stake by 41,400 shares [29] - Zhiwei Intelligent's actual controller has reduced its stake, bringing the total holding to 69% [30] Group 10 - Jincheng Co.'s actual controller plans to reduce its stake by up to 0.97% [31] - Jianghua Micro's chairman has reduced his stake by 1.09% [32] - COSCO Shipping Energy signed a shipbuilding contract worth 7.882 billion yuan [33] Group 11 - Dayu Water Saving's subsidiary is expected to win two high-standard farmland construction projects [34] - Guorui Technology's subsidiary is a candidate for the GXLF project [36] - ST Zhisheng has won a smart city governance project worth 104 million yuan [37]

Group 1 - *ST HuKe announced on December 12, 2025, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management [4] - For the first half of 2025, *ST HuKe's main business included agricultural products, particularly fresh-cut flowers and liquor grains, and chemical products, mainly titanium dioxide [4] Group 2 - In the third quarter, *ST HuKe reported revenue of 1.04 million yuan, a year-on-year decrease of 56.95%, with a net profit attributable to shareholders of 1.0271 million yuan [5] - As of December 12, 2025, *ST HuKe's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [6] Group 3 - Renfu Pharmaceutical announced on December 12, 2025, that it received a notice of administrative penalty from the CSRC for failing to disclose non-operating fund occupation and significant omissions in its annual reports for 2020 and 2022 [8] - The company will face risk warnings on its stock starting December 16, 2025, with a daily price limit of 5% after the warning is implemented [8] - Renfu Pharmaceutical, established in 1993, is a leading pharmaceutical company in Hubei, focusing on a full industrial chain from intermediates to drug formulations, and has a global presence with over 80 products exported to more than 70 countries [10] Group 4 - As of December 12, 2025, Renfu Pharmaceutical's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [11]

Group 1 - The core point of the news is that Renfu Pharmaceutical (SH 600079) will face a risk warning on its stock due to an administrative penalty notice from the China Securities Regulatory Commission, effective from December 16, 2025, with the stock being suspended from trading on December 15, 2025 [1] - The company's revenue composition for the year 2024 is as follows: pharmaceuticals account for 56.01%, pharmaceutical wholesale and related businesses account for 43.8%, and other businesses account for 0.19% [1] - As of the latest report, Renfu Pharmaceutical has a market capitalization of 29.6 billion yuan [2]

针对人福医药未及时披露2021年至2022年3月非经营性资金占用的行为，对人福医药给予警告，并处以 350万元的罚款；对人福医药2020年年度报告重大遗漏和虚假记载，2021年年度报告虚假记载，2022年 半年度报告虚假记载，2022年年度报告重大遗漏的行为，对人福医药给予警告，并处以500万元的罚 款；对当代集团指使人福医药2021年至2022年3月为其提供资金，导致人福医药未及时履行信息披露的 行为，对当代集团处以400万元的罚款；对当代集团指使人福医药2020年为其提供资金以及隐瞒关联关 系，导致人福医药2020年年度报告、2022年年度报告重大遗漏的行为，对当代集团处以500万元的罚 款。此外，艾路明、李杰、吴亚君等责任人也均处以罚款。 值得一提的是，艾路明作为时任当代集团董事，实际履行当代集团董事长职责，在人福医药信息披露违 法行为中居于核心地位，组织、领导案涉相关违法行为，与上市公司信息披露违法行为的发生具有紧密 联系。艾路明行为恶劣，情节特别严重，依据相关规定，拟决定对艾路明采取七年市场禁入措施。 北京商报讯（记者 丁宁）12月12日晚间，人福医药（600079）发布公告称，12月12日，公司及 ...

根据《上海证券交易所股票上市规则》第9.8.1、9.8.2条等相关规定，公司股票将于12月15日停牌1天， 12月16日起实施其他风险警示，实施其他风险警示后公司股票将在风险警示板交易，股票价格的日涨跌 幅限制为5%。 北京商报讯（记者 丁宁）12月12日晚间，人福医药（600079）发布公告称，公司于12月12日收到中国 证券监督管理委员会湖北监管局下发的《行政处罚事先告知书》，依据《行政处罚事先告知书》载明的 内容，根据相关规定，公司股票将被实施其他风险警示。 ...

公司于12月12日收到中国证券监督管理委员会湖北监管局下发的《行政处罚事先告知书》，依据相关法 规，公司股票将被实施其他风险警示。公司股票将于12月15日停牌1天，并于12月16日起实施其他风险 警示，实施后A股简称将变更为"ST人福"。 ...

每经AI快讯，12月12日，人福医药（600079）(600079.SH)公告称，公司于2025年12月12日收到中国证 券监督管理委员会湖北监管局下发的《行政处罚事先告知书》。根据中国证监会行政处罚事先告知书载 明的事实，公司披露的年度报告财务指标存在虚假记载，但未触及本规则第9.5.2条第一款规定情形，前 述财务指标包括营业收入、利润总额、净利润、资产负债表中的资产或者负债科目"等相关规定，公司 股票将被实施其他风险警示。实施后A股简称为ST人福，股票12月15日起停牌一天。 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-128 人福医药集团股份公司关于 收到中国证券监督管理委员会湖北监管局 《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 人福医药集团股份公司（以下简称"人福医药"或"公司"）及原控股股东武汉 当代科技产业集团股份有限公司（以下简称"当代科技"）于 2024 年 10 月 22 日收 到中国证券监督管理委员会（以下简称"中国证监会"）《立案告知书》（编号：证 监立案字 0052024007 号），因涉嫌信息披露违法违规，根据《中华人民共和国证券 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司及当代科技 立案。具体情况详见公司于 2024 年 10 月 23 日披露的《人福医药集团股份公司关于 公司及控股股东收到中国证券监督管理委员会立案告知书的公告》（公告编号：临 2024-108 号）。 2025 年 12 月 12 日，公司及相关责任人收到中国证监会湖北监管局出具的《行政 处罚事先告知书》（鄂处罚字〔2025〕8 ...

证券代码：600079 证券简称：人福医药 公告编号：2025-129 人福医药集团股份公司 关于实施其他风险警示暨停牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 第三节 实施其他风险警示的有关事项提示 根据《上海证券交易所股票上市规则（2025 年 4 月修订）》第 9.8.1、9.8.2 条等 相关规定，公司股票将于 2025 年 12 月 15 日停牌 1 天，2025 年 12 月 16 日起实施其 他风险警示，实施其他风险警示后公司股票将在风险警示板交易，股票价格的日涨跌 幅限制为 5%。 第四节 董事会关于争取撤销风险警示的意见及主要措施 证券停复牌情况：适用 因人福医药集团股份公司（以下简称"人福医药"或"公司"）于 2025 年 12 月 12 日收到中国证券监督管理委员会湖北监管局下发的《行政处罚事先告知书》（鄂处 罚字〔2025〕8 号），依据《行政处罚事先告知书》载明的内容，根据《上海证券交易 所股票上市规则（2025 年 4 月修订）》相关规定，公司股票将被实施其他风险警示。 ...